Jacobson TA et al. - Existing large-scale clinical trials such as the GISSI-Prevenzione Study and JELIS with low doses of n–3 FAs (1–2 g) show clinical benefit in reducing coronary heart disease without substantial changes in concentrations of TGs or other lipids.